Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Pharming Group N.V.    PHARM   NL0010391025

PHARMING GROUP N.V.

(PHARM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pharming Group N.V. : Buyers are coming back

01/13/2021 | 08:26am EST
long trade
Live
Entry price : 1.193€ | Target : 1.44€ | Stop-loss : 1.084€ | Potential : 20.7%
Shares in Pharming Group N.V. have recently benefitted from a regain of interest by market participants. The technical chart pattern suggests a continuation of the upward movement.
Investors have an opportunity to buy the stock and target the € 1.44.
Pharming Group N.V. : Pharming Group N.V. : Buyers are coming back
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • For a short-term investment strategy, the company has poor fundamentals.

Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalization (M$)Investor Rating
PHARMING GROUP N.V.-6.84%920
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159
ABBVIE INC.3.46%195 720
ELI LILLY AND COMPANY22.09%186 883
NOVO NORDISK A/S4.18%168 128
AMGEN INC.10.26%147 580
BRISTOL-MYERS SQUIBB COMPAN..4.08%145 890
More Results

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2020 184 M 224 M 224 M
Net income 2020 31,5 M 38,4 M 38,4 M
Net cash 2020 48,3 M 58,8 M 58,8 M
P/E ratio 2020 22,3x
Yield 2020 -
Capitalization 756 M 920 M 920 M
EV / Sales 2020 3,85x
EV / Sales 2021 2,88x
Nbr of Employees 258
Free-Float 98,5%
Upcoming event on PHARMING GROUP N.V.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 2,15 €
Last Close Price 1,19 €
Spread / Highest target 162%
Spread / Average Target 81,3%
Spread / Lowest Target 51,1%
EPS Revisions
Managers and Directors
NameTitle
Sijmen de Vries Chairman-Management Board & CEO
Paul Jai Sekhri Chairman
Mireille Sanders Senior Vice President-Operations
Jeroen Henk Wakkerman Chief Financial Officer
Bruno M. L. Giannetti Chief Medical Officer